Locations:
Search IconSearch

How Do Patient Characteristics Impact Treatment Time in Acute Stroke? (Video)

Study of thrombolysis therapy timing on mobile stroke unit sheds light

Do certain patient characteristics influence the speed of intravenous thrombolysis delivery and door-to-needle time in acute stroke management? The answer is yes, according to a Cleveland Clinic study presented at the 2018 International Stroke Conference.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The researchers reviewed 124 patients with acute stroke treated with IV thrombolysis on Cleveland Clinic’s mobile stroke treatment unit over three years following the unit’s launch in 2014. Their aim was to identify characteristics associated with more rapid treatment delivery in hopes of potentially refining processes of care. The findings are likely to apply to acute stroke patients in treatment settings beyond mobile stroke units.

In this 90-second video, coinvestigator Andrew Russman, DO, shares the study’s findings on which patient characteristics most influenced treatment time and potential reasons why.

When] we look at the population of patients that we’ve been treating since 2014 with IV TPA or alteplase, what we can see is that that population has certain characteristics that lead to them being treated earlier and more efficiently. And those characteristics are probably not different on the mobile stroke unit than they are let’s say in the emergency department. But when we look at minimal mobile stroke, we can really see that… if you present and you have weakness of an extremity, especially an arm weakness that’s very obvious, that ends up being a very hard indicator that usually leads to us pre-mixing the TPA. And then we’re more effective. Once we’ve pre-mixed TPA, we get that CT scan, and as soon as that CT scan is done and we’ve got the necessary laboratory and other information, we’re able to give the IV TPA. And if we have softer symptoms, like subtleties of language or speech, or there’s more sensory changes or there’s a group of different symptoms that may add up to enough disability to warrant giving IV TPA, they’re sometimes less obvious than that focal weakness of the extremity.

Advertisement

Related Articles

16-NEU-2800-Kubu-101058161-650×450
What Do Patients Want from DBS for Parkinson’s Disease?

New study advances understanding of patient-defined goals

photo of a man sleeping at a desk, with a podcast icon overlay
March 15, 2024/Neurosciences/Podcast
Diagnosis and Management of Idiopathic Hypersomnia (Podcast)

Testing options and therapies are expanding for this poorly understood sleep disorder

illustration of an alzheimer brain and a packet of sildenafil pills
March 11, 2024/Neurosciences/Research
Sildenafil as an Alzheimer’s Candidate Drug: Further Support From Insurance Database and Mechanistic Studies

Real-world claims data and tissue culture studies set the stage for randomized clinical testing

brain scan showing perimesencephalic subarachnoid hemorrhage
Study Supports Less-Strict Monitoring for Nonaneurysmal Perimesencephalic SAH Without Hydrocephalus

Digital subtraction angiography remains central to assessment of ‘benign’ PMSAH

illustrated brain with the letters "AI" on a computer circuit board
As AI Tools Emerge, Be Proactive and Engaged to Shape Their Development

Cleveland Clinic neuromuscular specialist shares insights on AI in his field and beyond

histology image of a gray matter lesion in a multiple sclerosis brain
Study Suggests Protective Role for Microglia at Borders of Gray Matter Lesions in Progressive MS

Findings challenge dogma that microglia are exclusively destructive regardless of location in brain

series of digital-looking brain icons with a podcast button overlay on top
March 1, 2024/Neurosciences/Podcast
Harnessing the Power of AI in Medicine (Podcast)

Neurology is especially well positioned for opportunities to enhance clinical care and medical training

illustration of a neuron affected by multiple sclerosis
Clinical Trials in Progressive MS: An Assessment of Advances and Remaining Challenges

New review distills insights from studies over the past decade

Ad